Literature DB >> 10407147

Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells.

X He1, S R Miranda, X Xiong, A Dagan, S Gatt, E H Schuchman.   

Abstract

A rapid purification method was developed to isolate milligram quantities of human acid sphingomyelinase from the media of overexpressing Chinese hamster ovary cells. The purified, recombinant enzyme (rhASM) had physical and kinetic characteristics that were consistent with those reported for the non-recombinant enzyme, including an acidic pH optimum and sensitivity to sulfhydryl reducing reagents and the zinc specific chelator, 1, 10-phenanthroline. A novel assay using fluorescently conjugated sphingomyelin was developed to explore the substrate binding properties of rhASM. Substrate binding required a fatty acid chain length of at least six carbons and the presence of the phosphocholine headgroup on sphingomyelin. Substrate binding also required an acidic pH, and was inhibited by pretreatment of the enzyme with sulfhydral reducing reagents or 1,10-phenanthroline. rhASM was rapidly internalized by cultured skin fibroblasts from Niemann-Pick disease (NPD) patients, and approximately 50% of this uptake was dependent on the mannose 6-phosphate receptor system. Studies using FITC-labeled rhASM revealed that by 1 h the internalized enzyme was localized to acidic compartments and could degrade sphingomyelin, the first demonstration that a lysosomal sphingolipid hydrolase can be fluorescently labeled and retain its biological activity. Intravenous injection of rhASM into ASM knock-out mice showed that the t(1/2) in the plasma was less than 5 min, and that the majority of the injected enzyme was taken up by the liver, followed by the spleen. Thus, these studies lay the foundation for future structure/function investigations of ASM, further investigations into this enzyme's role in ceramide mediated signal transduction, and the evaluation of enzyme replacement therapy for NPD using the mouse model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10407147     DOI: 10.1016/s0167-4838(99)00069-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  31 in total

1.  A DNA nanomachine chemically resolves lysosomes in live cells.

Authors:  KaHo Leung; Kasturi Chakraborty; Anand Saminathan; Yamuna Krishnan
Journal:  Nat Nanotechnol       Date:  2018-12-03       Impact factor: 39.213

2.  The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations.

Authors:  Calogera M Simonaro; Robert J Desnick; Margaret M McGovern; Melissa P Wasserstein; Edward H Schuchman
Journal:  Am J Hum Genet       Date:  2002-10-04       Impact factor: 11.025

3.  A novel mechanism of lysosomal acid sphingomyelinase maturation: requirement for carboxyl-terminal proteolytic processing.

Authors:  Russell W Jenkins; Jolanta Idkowiak-Baldys; Fabio Simbari; Daniel Canals; Patrick Roddy; Clarke D Riner; Christopher J Clarke; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

4.  δ-Tocopherol Effect on Endocytosis and Its Combination with Enzyme Replacement Therapy for Lysosomal Disorders: A New Type of Drug Interaction?

Authors:  Rachel L Manthe; Jeffrey A Rappaport; Yan Long; Melani Solomon; Vinay Veluvolu; Michael Hildreth; Dencho Gugutkov; Juan Marugan; Wei Zheng; Silvia Muro
Journal:  J Pharmacol Exp Ther       Date:  2019-05-17       Impact factor: 4.030

5.  Altered Clathrin-Independent Endocytosis in Type A Niemann-Pick Disease Cells and Rescue by ICAM-1-Targeted Enzyme Delivery.

Authors:  Jeff Rappaport; Rachel L Manthe; Carmen Garnacho; Silvia Muro
Journal:  Mol Pharm       Date:  2015-04-23       Impact factor: 4.939

6.  Characterization of common SMPD1 mutations causing types A and B Niemann-Pick disease and generation of mutation-specific mouse models.

Authors:  Iwan Jones; Xingxuan He; Fourogh Katouzian; Peter I Darroch; Edward H Schuchman
Journal:  Mol Genet Metab       Date:  2008-09-23       Impact factor: 4.797

Review 7.  The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases.

Authors:  Eric L Smith; Edward H Schuchman
Journal:  FASEB J       Date:  2008-06-20       Impact factor: 5.191

8.  Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers.

Authors:  Silvia Muro; Carmen Garnacho; Julie A Champion; John Leferovich; Christine Gajewski; Edward H Schuchman; Samir Mitragotri; Vladimir R Muzykantov
Journal:  Mol Ther       Date:  2008-06-17       Impact factor: 11.454

9.  Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes.

Authors:  Iason Papademetriou; Zois Tsinas; Janet Hsu; Silvia Muro
Journal:  J Control Release       Date:  2014-06-14       Impact factor: 9.776

10.  Exocytosis of acid sphingomyelinase by wounded cells promotes endocytosis and plasma membrane repair.

Authors:  Christina Tam; Vincent Idone; Cecilia Devlin; Maria Cecilia Fernandes; Andrew Flannery; Xingxuan He; Edward Schuchman; Ira Tabas; Norma W Andrews
Journal:  J Cell Biol       Date:  2010-06-07       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.